Oxford Biomedica PLC Oxford BioMedica Block listing Application (2735R)
June 25 2015 - 10:40AM
UK Regulatory
TIDMOXB
RNS Number : 2735R
Oxford Biomedica PLC
25 June 2015
Oxford BioMedica
Block listing Application
Oxford, UK - 25 June 2014: Oxford BioMedica plc ("OXB" or "the
Group") (LSE: OXB), a leading gene and cell therapy group,
announces that application has been made to the Financial Conduct
Authority and the London Stock Exchange for admission to (i) the
Premium segment of the Official List and (ii) to trading on the
London Stock Exchange's markets for a block listing of securities
totalling 22 million ordinary shares of 1 pence each (the "Ordinary
Shares").
The Ordinary Shares are being reserved under a block listing and
will be issued from time to time pursuant to the Group's LTIP.
It is expected that admission of the Ordinary Shares will become
effective on 26 June 2015. The Ordinary Shares will rank pari passu
in all respects with the Group's existing ordinary shares in
issue.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy Group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that
are inadequately treated today, including ocular and central
nervous system disorders. OXB Solutions, the Group's
industry-leading manufacturing and development business, provides
services to collaborators and partners working in gene and cell
therapy, including Novartis and Immune Design Corp. In addition,
the Group has licenced products and IP to Sanofi, Pfizer,
GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent
BioSolutions and ImaginAb. Further information is available at
www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRPKPDNQBKDAAB
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024